Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Altered pathways as a biomarker for disease outcomes in CLL

Carsten Niemann • 9 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia

Carsten Niemann, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, describes how the number of signaling pathways altered by driver mutations in chronic lymphocytic leukemia (CLL) impacts disease outcome. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Paper: https://clincancerres.aacrjournals.org/content/26/6/1507

More from Carsten Niemann

The PreVent-ACaLL trial: treating patients with CLL who are at high risk of infections 2:55
The PreVent-ACaLL trial: treating patients with CLL who are at high risk of infections
Carsten Niemann • 7 Dec 2024
Updates to the ESMO clinical practice guidelines for CLL 2:19
Updates to the ESMO clinical practice guidelines for CLL
Carsten Niemann • 7 Dec 2024
Developing open-source algorithms to improve outcomes for patients with hematological malignancies 2:29
Developing open-source algorithms to improve outcomes for patients with hematological malignancies
Carsten Niemann • 7 Dec 2024
Driver mutations predicting clinical outcomes upon MRD-guided venetoclax plus ibrutinib in R/R CLL 1:50
Driver mutations predicting clinical outcomes upon MRD-guided venetoclax plus ibrutinib in R/R CLL
Carsten Niemann • 7 Dec 2024

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals